Gene: VRK1

7443
PCH1|PCH1A
vaccinia related kinase 1
protein-coding
14q32.2
Ensembl:ENSG00000100749 MIM:602168 Vega:OTTHUMG00000171459 UniprotKB:Q99986
NG_016293.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.330e-1 (AD)  4.111e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GSTA40.9
FARSB0.899
EID2B0.887
SCG50.883
SRP190.881
C5orf220.881
HENMT10.881
WDR540.878
HPRT10.877
TAF90.877

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.479
OR4F29-0.448
AJUBA-0.445
RUNX3-0.444
WDR38-0.442
EVC2-0.435
CCDC102A-0.431
SYDE1-0.409
CNN2-0.407
FOXJ1-0.406

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of VRK1 mRNA"19114083
C0294972,3-bis(3'-hydroxybenzyl)butyrolactone"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of VRK1 mRNA"19167446
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VRK1 mRNA"23196670
D000082AcetaminophenAcetaminophen results in increased expression of VRK1 mRNA22230336
D016604Aflatoxin B1Aflatoxin B1 affects the expression of VRK1 protein20106945
C015001arsenitearsenite results in decreased expression of VRK1 mRNA18929588
D001205Ascorbic Acid[Tretinoin co-treated with Ascorbic Acid] results in decreased expression of VRK1 mRNA16443354
D001280AtrazineAtrazine results in decreased expression of VRK1 mRNA22378314
D001379AzathioprineAzathioprine results in decreased expression of VRK1 mRNA22623647
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of VRK1 mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of VRK1 mRNA19770486
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of VRK1 mRNA22228805
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of VRK1 mRNA"20382639
D004958EstradiolEstradiol results in increased expression of VRK1 mRNA19167446
C006780bisphenol Abisphenol A affects the expression of VRK1 mRNA21786754
C006780bisphenol Abisphenol A results in decreased expression of VRK1 mRNA29275510
D002220CarbamazepineCarbamazepine affects the expression of VRK1 mRNA25979313
C074702chromium hexavalent ionchromium hexavalent ion affects the expression of VRK1 mRNA28472532
D019327Copper SulfateCopper Sulfate results in decreased expression of VRK1 mRNA19789285
D019327Copper SulfateCopper Sulfate results in increased expression of VRK1 mRNA19789285
D003375Coumestrol"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of VRK1 mRNA"19167446
D003375Coumestrol[Coumestrol co-treated with resveratrol] results in increased expression of VRK1 mRNA19167446
D003375CoumestrolCoumestrol results in increased expression of VRK1 mRNA19167446
D016572CyclosporineCyclosporine results in decreased expression of VRK1 mRNA20106945|2163298
D000069439DasatinibDasatinib results in decreased expression of VRK1 mRNA20579391
C000944dicrotophosdicrotophos results in decreased expression of VRK1 mRNA28302478
D002117CalcitriolCalcitriol results in decreased expression of VRK1 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in decreased expression of VRK1 mRNA21592394
C015835dimethyl-4-toluidinedimethyl-4-toluidine results in increased expression of VRK1 mRNA27638505
C024629dimethyl phthalatedimethyl phthalate affects the expression of VRK1 mRNA26924002
D004791Enzyme Inhibitors[Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of VRK1 protein23301498
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VRK1 mRNA22079256
C492448ICG 001ICG 001 affects the expression of VRK1 mRNA26191083
C492448ICG 001ICG 001 results in decreased expression of VRK1 mRNA26191083
D007213IndomethacinIndomethacin results in increased expression of VRK1 mRNA28201806
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VRK1 mRNA25613284
C544151jinfukangjinfukang results in increased expression of VRK1 mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of VRK1 mRNA24796395|2725927
C517284monomethyl phthalatemonomethyl phthalate affects the expression of VRK1 mRNA26924002
D009151Mustard GasMustard Gas results in decreased expression of VRK1 mRNA25102026
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of VRK1 mRNA"25554681
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of VRK1 mRNA25729387
C030110oxaliplatinoxaliplatin results in decreased expression of VRK1 mRNA25729387
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of VRK1 protein26879310
D010894PiroxicamPiroxicam results in decreased expression of VRK1 mRNA21858171
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VRK1 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of VRK1 mRNA22079256
D011794QuercetinQuercetin results in increased expression of VRK1 mRNA21632981
C059514resveratrol[Coumestrol co-treated with resveratrol] results in increased expression of VRK1 mRNA19167446
D013739Testosterone[Testosterone co-treated with Calcitriol] results in decreased expression of VRK1 mRNA21592394
D013739TestosteroneTestosterone results in decreased expression of VRK1 mRNA21592394
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of VRK1 mRNA22574217
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of VRK1 mRNA21802500
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of VRK1 mRNA21570461
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VRK1 mRNA25613284
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of VRK1 mRNA25729387
D014212Tretinoin[Tretinoin co-treated with Ascorbic Acid] results in decreased expression of VRK1 mRNA16443354
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of VRK1 mRNA"26179874
C057693troglitazonetroglitazone results in decreased expression of VRK1 mRNA19140230
D014520UrethaneUrethane results in decreased expression of VRK1 mRNA28818685
D014635Valproic AcidValproic Acid affects the expression of VRK1 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of VRK1 mRNA29154799
D014640VancomycinVancomycin results in decreased expression of VRK1 mRNA18930951
D001335Vehicle EmissionsVehicle Emissions affects the methylation of VRK1 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004672protein kinase activity-IDA22194607  
GO:0004674protein serine/threonine kinase activity-IBA21873635  
GO:0004674protein serine/threonine kinase activity-IDA21543316  
GO:0004674protein serine/threonine kinase activity-TAS-  
GO:0005515protein binding-IPI15105425  15378002  15542844  18617507  19103756  21920476  
22194607  22621922  24492002  25609649  25923214  26869104  
29340707  
GO:0005524ATP binding-IEA-  
GO:0019901protein kinase binding-IDA22572157  
GO:0031493nucleosomal histone binding-IPI22194607  
GO:0035175histone kinase activity (H3-S10 specific)-IDA22194607  
GO:0072354histone kinase activity (H3-T3 specific)-IDA22194607  
GO ID GO Term Qualifier Evidence PubMed
GO:0006468protein phosphorylation-IDA22194607  
GO:0007077mitotic nuclear envelope disassembly-TAS-  
GO:0007084mitotic nuclear envelope reassembly-TAS-  
GO:0018105peptidyl-serine phosphorylation-IBA21873635  
GO:0043987histone H3-S10 phosphorylation-IDA22194607  
GO:0046777protein autophosphorylation-IDA21543316  22194607  
GO:0051301cell division-IEA-  
GO:0072355histone H3-T3 phosphorylation-IDA22194607  
GO:0090166Golgi disassembly-IDA19103756  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-IDA22194607  
GO:0005654nucleoplasm-IDA-  
GO:0005654nucleoplasm-TAS-  
GO:0005730nucleolus-IDA-  
GO:0005737cytoplasm-IBA21873635  
GO:0005795Golgi stack-IDA19103756  
GO:0005819spindle-IEA-  
GO:0005829cytosol-IDA-  
GO:0005829cytosol-TAS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1640170Cell CycleTAS
R-HSA-2555396Mitotic Metaphase and AnaphaseTAS
R-HSA-2980766Nuclear Envelope BreakdownTAS
R-HSA-2993913Clearance of Nuclear Envelope Membranes from ChromatinTAS
R-HSA-2995383Initiation of Nuclear Envelope ReformationTAS
R-HSA-2995410Nuclear Envelope ReassemblyTAS
R-HSA-68875Mitotic ProphaseTAS
R-HSA-68882Mitotic AnaphaseTAS
R-HSA-68886M PhaseTAS
R-HSA-69278Cell Cycle, MitoticTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26940775A genetic view of laryngeal cancer heterogeneity. (2016 May 2)de Miguel-Luken MJCell Cycle